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Abstract
The pathomechanism of mycosis fungoides (MF), the most common type of primary cutaneous T-cell lymphomas
(CTCLs) and a malignancy of non-recirculating, skin-resident T-cells, is unknown albeit underlying viral infections
have been sought for. Human endogenous retroviruses (HERVs) are ancient retroviral sequences in the human
genome and their transcription is often deregulated in cancers. We explored the transcriptional activity of HERV
sequences in a total of 34 samples comprising MF and psoriasis skin lesions, as well as corresponding non-
malignant skin using a retrovirus-specific microarray and quantitative RT-PCR. To identify active HERV-W loci, we
cloned the HERV-W specific RT-PCR products, sequenced the cDNA clones and assigned the sequences to HERV-
W loci. Finally, we used immunohistochemistry on MF patient and non-malignant inflammatory skin samples to
confirm specific HERV-encoded protein expression. Firstly, a distinct, skin-specific transcription profile consisting of
five constitutively active HERV groups was established. Although individual variability was common, HERV-W
showed significantly increased transcription in MF lesions compared to clinically intact skin from the same patient.
Predominantly transcribed HERV-W loci were found to be located in chromosomes 6q21 and 7q21.2, chromosomal
regions typically altered in CTCL. Surprisingly, we also found the expression of 7q21.2/ERVWE1-encoded Syncytin-1
(Env) protein in MF biopsies and expression of Syncytin-1 was seen in malignant lymphocytes, especially in the
epidermotropic ones, in 15 of 30 cases studied. Most importantly, no Syncytin-1 expression was detected in
inflammatory dermatosis (Lichen ruber planus) with skin-homing, non-malignant T lymphocytes. The expression of
ERVWE1 mRNA was further confirmed in 3/7 MF lesions analyzed. Our observations strengthen the association
between activated HERVs and cancer. The study offers a new perspective into the pathogenesis of CTCL since we
demonstrate that differences in HERV-W transcription levels between lesional MF and non-malignant skin are
significant, and that ERVWE1-encoded Syncytin-1 is expressed in MF lymphoma cells.
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Introduction
CTCLs represent a group of heterogenous non-Hodgkin
lymphomas arising mostly from CD4+ T-cells. The clinical
behavior of these lymphomas varies from a non-progressive
early mycosis fungoides (MF) to rapidly progressing leukaemic
Sézary syndrome (SS) [1,2]. The most common type of
CTCL, MF represents a malignancy of skin-homing T-cells, i.e.
sessile, non-recirculating, skin-resident effector memory T-cells
(TEM) [3]. Thus, the T-cell clone in the skin is infrequently found
in peripheral blood and may differ from the one in the skin [4].
While CTCLs show a growing incidence, the underlying
mechanisms are still largely unknown and no curative therapy
exists so far.
Chromosomal instability is a typical feature of CTCL.
Chromosome aberrations are diverse including numerical (DNA
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copy number changes) as well as structural (deletions,
translocations, inversions) alterations. Frequently altered
chromosomes include chromosomes 1, 2, 3, 6, 7, 8, 9, 10, 11,
12, 13, 14, 16, 17, and 19, but almost any chromosome can be
involved [5-12].
With regard to CTCL pathogenesis, there are currently two
main hypotheses. The antigen stimulation hypothesis suggests
that persistent antigen stimulation leads to a continuous
proliferation of T-cells and chronic inflammation, ultimately
leading to the development of a malignant T-cell clone [13].
The second hypothesis suggests that a specific viral agent may
serve as a triggering factor (antigen) [14]. Since MF, the most
common form of CTCL, clinically resembles the smoldering
form of adult T-cell lymphoma/leukemia, caused by human T-
cell leukaemia/lymphoma virus I (HTLV-I) and since CTCL
patients also have antibodies cross-reacting with HTLV-I and/or
human immunodeficiency virus type 1 (HIV-1) core proteins
[15,16] exogenous retroviruses were extensively sought for as
an etiologic agent. However, neither replicating retroviruses nor
any other viruses have been found in CTCL [17-22].
Human endogenous retroviruses (HERVs), on the other
hand, represent a group of repetitive elements in the human
genome. HERVs and related LTR-retroelements comprise
about 8% of the human genome and at least HERVs stem from
ancient retroviral infections of the germ cell genome. In
primates, a major invasion and expansion of pol containing
ERVs occurred after the New World Monkeys lineage
separated from the Old World Monkeys and apes [23]. HERV
elements, if they are full-length proviruses, comprise promoters
and other transcription-regulatory elements within long-
terminal-repeats (LTR), harbor genes for retroviral proteins
(Gag, Pro, Pol, and Env) and some HERV groups even encode
accessory proteins (for review, see 24 and HERVs and cancer
[25-27].
Since initial germ line infection, HERVs amplified in copy
numbers and almost all loci accumulated numerous mutations,
thereby becoming coding-deficient [28,29]. Nevertheless,
transcription of HERV elements may be re-activated e.g. by
various environmental conditions such as chemicals, radiation
or exogenous viruses [30-33]. In animals, recombination
between different ERVs, or exogenous viruses and ERVs,
resulted in novel pathogenic viruses causing leukemia and
other tumors [34]. However, no infectious HERV has been
detected in human. Instead, polymorphic HERVs, specifically
presence/absence alleles of HERV proviral loci, have been
reported (for a review, see 35.
Transcription of HERVs has been reported for all human
tissues investigated so far, including healthy individuals
[36-39]. Generally, HERVs are transcribed in a tissue-specific
manner [40,41] and different cell types, each with a specific
HERV transcription pattern, in a tissue are likely to determine
the HERV transcription pattern of that tissue as a whole.
Additionally, transcription of HERVs appears deregulated in
cancers (for a review, see 25,42) and also inflammation may
play a role in HERV activation. It is under debate though,
whether inflammation is the cause or consequence of HERV
activation [43-45]. For example, cytokines such as TNF-α are
known to regulate HERV expression [46,47]. Although not
proven, this may have affected the expression of a new
endogenous retroviral variant found in psoriasis [48]. Moreover,
functional regulatory sequences within HERV LTRs could affect
transcriptional regulation of neighboring genes, e.g. activation
of oncogenes or inactivation of tumor suppressor genes
[25,49-53]. Notably, some HERVs still code for functional
proteins, some of which might be associated with human
diseases, like HERV-K (HML-2) encoded Rec or Np9 [25,52].
A locus of the human endogenous retrovirus group HERV-W
has evolved to an essential gene (ERVWE1) that encodes
Syncytin-1 and exerts important functions during placenta
formation [54-56]. Syncytin-1 has also been implicated in the
development of Multiple Sclerosis (MS) [57]. Besides
Syncytin-1, sequences of unclear origin very similar to genomic
HERV-W sequences and named Multiple sclerosis associated
retrovirus (MSRV) have been reported [58]. Yet, the nature of
those sequences was interpreted controversially [59].
We studied here the expression of HERVs in CTCL by
investigating HERV transcription profiles and identifying active
HERV loci in MF, in psoriasis skin lesions, and in
corresponding, clinically intact skin of each patient. We further
identified the transcribed HERV-W loci and examined HERV-
W-derived Syncytin-1 expression both in MF and in non-
malignant, inflammatory tissue samples.
Results
The purpose of this investigation was to establish, for the first
time, an overall endogenous retroviral transcription profile for
MF skin and to evaluate the possible implications of
differentially active retroviral elements in CTCL pathogenesis.
Skin biopsies of psoriasis patients with no known malignant
diseases served as a reference due to previously reported
expression of HERV families HERV-W, K and E [48]. Of note,
since HERVs show tissue-specific expression profiles (Table
S1), and since MF, unlike Sezary syndrome, is a malignancy of
sessile, non-recirculating skin-resident T-cells [4], only skin
biopsies with such skin-resident lymphocytes were studied.
A distinct, skin-specific HERV transcription profile
identified in the skin of MF and psoriasis patients
A retrovirus-specific microarray (RetroArray), previously
described in detail [60], was used to define a distinct skin-
specific HERV transcription profile [60]; see also Methods). In
this semi-quantitative analysis, seven constitutively transcribed
HERV taxa derived from five HERV groups (HERV-E, HERV-F,
HERV-W, ERV9, HERV-K (HML-4) were detected in at least
90% of healthy skin samples (Figure 1). This HERV core
transcription pattern was compared with the HERV core
signature of other human tissues such as brain, mamma,
urothelium, and kidney (see Table S1 for detailed information).
In contrast to all other tissues investigated so far, primarily
class I HERVs were found to be active in skin, whereas class II
HERVs are less frequently transcribed. Since the array also
contained probes specific for HTLV and HIV sequences
transcripts from such retrovirus sequences should have been
detected if present. Yet, all cases tested negative (data not
shown).
HERV-W Expression in Mycosis Fungoides
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Figure 1.  Retroarray analysis of HERV transcriptional activity in MF.  HERV activity profiles representing pairs of lesion (A) and
non-malignant (B) skin tissue specimens (digitally aligned). Each sample pair (n=17) was derived from an individual patient (MF
1-12, psoriasis 13-17). HERV subgroups representing a skin-specific core transcription profile (HERV-E, HERV-F, HERV-W, ERV-9,
HERV-K(HML-4)) are emphasized with red letters. A panel of housekeeping genes (Ubiquitin, GAPDH, RPL19, β-Actin, HPRT)
served as internal controls (for detailed information on methodology, see [77,79]). Each positive spot on the microarray may
represent multiple HERV loci of one subgroup of multicopy HERV elements with sufficient sequence similarity that individual
elements cannot be distinguished. Weak signals may be unrecognizable in the printed figure.
doi: 10.1371/journal.pone.0076281.g001
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In order to search for disease-related HERV activity, we then
compared the signatures of paired MF lesion (A) and non-
malignant skin (B) tissue samples from each individual (Figure
1). In this semi-quantitative array analysis, the transcription
patterns of lesion samples were generally similar to those of
non-malignant skin, in both MF and psoriasis patients, and
showed only gradual differences in signal intensities. However,
with the exception of patient 2 showing a HERV-H signal in
non-malignant tissue but not in the lesion, a tendency towards
increased HERV transcript levels in lesional tissue was
observed at an individual level. The foremost group, HERV-W,
appeared to be upregulated in skin lesions of MF patients
compared to non-malignant skin. In addition, HERV-K (HML-6)
and HERV-R showed some minor differences in transcript
levels between non-malignant and lesion skin samples in both,
MF and psoriasis patients (Figure 1). In contrast, low-level
transcription of HERV-K (HML-2), and HML-3 was detected in
lesion and/or non-malignant samples of a few MF patients, but
not in any of the psoriasis patients.
Significantly increased HERV-W transcript levels in
mycosis fungoides
We next confirmed the differential HERV-W transcript levels
identified with the semi-quantitative RetroArray analysis by
quantitative RT-PCR on paired tissue samples of a
representative set of patients. Of note, since the primers used
in the RetroArray, amplify nearly all retroviral pol sequences
(and since the amplification product would be too small), new
primers were designed for the qRT-PCR in such a way that one
primer matched the capture probe sequences spotted on the
microarray, whereas the second primer was located 70 bp
downstream of the first primer (see Methods). With qRT-PCR,
the level of HERV-W transcripts was found to be significantly
increased in 6 out of 9 (67%) MF skin lesions studied
(representing disease stages IA-IVA and one folliculotropic MF,
Figure 2).
Identification of transcribed HERV-W loci
To identify active HERV-W loci, we next cloned the HERV-W
specific RT-PCR products, sequenced randomly selected
cDNA clones and assigned the cDNA sequences to HERV-W
loci based on characteristic sequence differences between the
various HERV-W env genes as described before [59]. With this
Figure 2.  Relative quantification of specific HERV-W transcript levels.  Lesion (A) and non-malignant (B) cDNAs from each
patient (patients 1-8, 12, representing stages III, IA, IVA, fMF, fMF, IB, IA, IB, IB, in respective order) were amplified using HERV-W
specific primers (targeting a region within the pol gene) and normalized with housekeeping gene RNA polymerase II. Lesion
samples are depicted by dark grey bars, non-malignant intact skin samples by light gray bars. No data in patient1B and patient 2B
means there was no detectable transcription. Relative mRNA expression levels are given as mean ±SD. Statistical significance is
presented as *p<0.05, **p>0.02, and ***p<0.01. Concordance between the microarray and qRT-PCR data is not complete due to
the differences in primer specificities (see Methods). fMF= folliculotrophic MF.
doi: 10.1371/journal.pone.0076281.g002
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method, the cloning frequency of cDNAs, i.e. transcripts from a
HERV-W locus, roughly correlates with the transcript level of
that specific HERV-W locus relative to other transcribed HERV-
W loci.
We sequenced between 22 and 38 (average: 29) cDNA
clones from the MF lesion and non-malignant tissues of four
patients (from which sufficient amount of cDNA was available).
By so doing, we identified eight different HERV-W loci on
chromosomes 5q21.3, 6q21, 7q21.2, 11p14.3, 12q13.13,
15q21.3, 17q12, and Xq22.3 as transcribed in at least one of
the samples (Figure 3 and Table S2). Though conditions for
amplification of transcripts derived from different HERV-W loci
were the same, the number and the identity of transcribed
HERV-W loci differed markedly between lesion and non-
malignant tissue samples (Figure 3, Table S2). The HERV-W
locus on chromosome 6q21 was cloned as cDNA most often,
and transcribed at a higher level in MF lesion tissue than in the
non-malignant tissue samples. HERV locus 5q21.3 was
transcribed in non-lesional skin only while 17q12 was
transcribed in both lesional and non-lesional tissue.
Interestingly, in the MF lesional sample of patient 5, HERV-W
transcripts appeared to be derived predominantly or exclusively
(28/28 cDNA clones) from the 7q21.2 / ERVWE1 locus. In
summary, the highest, total numbers of cDNAs found in MF
skin lesions and outnumbering the corresponding number in
non-lesional skin were assigned to HERV-W loci 6q21 and in
7q21.2 (Figure 3, Table S2).
Five of these loci had been identified as transcribed in a
recent study (see Table S1 and [59,61]). Thus, elevated HERV-
W transcript levels detected by qRT-PCR in MF lesions appear
to be due to up regulation of specific HERV-W loci, such as
those located in 6q21 or 7q21.2. As for coding capacity of
transcribed HERV-W loci, all loci but two display several
frameshifts and stop mutations within the coding region for the
Env protein. Therefore, protein production from those loci
seems less likely. Importantly, the HERV-W locus in 7q21.2,
ERVWE1, encodes a functional Env protein (Syncytin-1) that is
crucially involved in placental morphogenesis [54-56]. Coding
capacity of the transcribed ERVWE2 locus in Xq22.3 has been
addressed recently [62].
Figure 3.  Transcriptional activity of HERV-W proviral loci in lesion and non-malignant skin tissue with MF.  HERV-W
transcripts were amplified using HERV-W env derived primers, cloned, sequenced and assigned to proviral loci as described
previously [59]. For each proviral locus the relative cloning frequency is given as % of the total number of analyzed clones per skin
tissue. HERV-W loci 6q21 and 7q21, 2 showed the highest relative cloning frequency, thus relative transcript levels in MF-lesions.
doi: 10.1371/journal.pone.0076281.g003
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ERVWE1 mRNA is present in mycosis fungoides skin
lesions but not in benign lymphocyte infiltrates of the
skin
Because a portion of the HERV-W transcripts were shown to
be derived from the 7q21.2/ERVWE1 locus, we used
confirmatory Taqman qPCR to analyze the expression of
ERVWE1 mRNA in the MF lesions and also, for comparison, in
five Lichen ruber planus skin samples (representing benign
skin-homing T cell infiltrates). ERVWE1 expression was
detectable in 3/7 (43%) MF lesions analysed (Figure 4). The
crossing point (CP) –values of ERVWE1 ranged from 34 to 37
(see amplification curves as supportive information in Figure
S1). GAPDH served as internal standard and was expressed in
every sample (CP-values ranging from 19 to 23). The standard
deviation within a sample pair (H, clinically non-lesional, i.e.
healthy-looking skin vs. MF lesion) was less than 0.5 on
average. Samples of the MF lesions of patients 3 and 7 were
also analysed, but no expression was detected (Figure S1). On
the contrary, patient 18 showed expression in both samples
and patient 7 only in the non-lesional skin (Figure S1). Both of
these patients had abundant numbers of MF patches and
plaques over their skin at the time of biopsy, so although
clinically healthy-looking, the skin may have been diseased.
Most importantly, no ERVWE1 mRNA expression was found in
any of the five Lichen ruber planus samples studied (Figure
S1).
Syncytin-1 protein is expressed in mycosis fungoides
skin lesions but not in lichen ruber planus
Since HERV-W transcripts derived from the 7q21.2/ERVWE1
locus were frequently up regulated in the MF lesion tissue
(Figures 3-4, S1), we next sought for possible expression of
ERVWE1 encoded Syncytin-1 (Env) protein. For this, we used
monoclonal antibody 1F11B10, shown to recognize the
surface-associated (SU) subunit of Syncytin-1, and
immunohistochemistry (IHC) of an extended series of formalin-
fixed, paraffin-embedded (FFPE)-skin biopsies, including also
five samples of lichen ruber planus, an inflammatory
dermatosis with abundant infiltrate of T lymphocytes. IHC
revealed clear expression of Syncytin-1 in a varying number of
lymphocytes in the sub-epidermal infiltrates or in individual
lymphocytes invading the epidermis in 15/30 (50%) of the
investigated MF cases (n=30, Figure 5, details in Methods).
Typically, most abundant Syncytin-1 expression was seen in
morphologically malignant lymphocyte clusters within the
characteristic Pautrier’s microabscesses in the epidermis
(Figure 5A-B). Syncytin-1 protein expression was detected in
all but one (patient 5) of those MF skin samples from which
active HERV loci had been cloned (Figure 3). No Syncytin-1
expression was detected in any of the lichen ruber planus
samples (Figure 5D).
Additionally, patients 1, 7, 8, and 12 were available for serum
sampling and their sera were examined for HERV-Wenv auto-
antibodies using HERV recombinant ERVWE1 protein as
antigen in ELISA assay. Serum from patient 12 showed
antibody reactivity against this protein at a detectable level (OD
value 0.8-1.0 with serum dilution 1:250, data not shown).
Patient 12 was a male - thus not naturally sensitized to
Syncytin-1 from placental expression of Syncytin-1 during
pregnancy - and the only study subject without specific
treatment during the preceding year and with relapsing skin
lesions in three restricted skin regions.
Discussion
This is the very first study to examine the transcription of
HERVs in MF, the most common form of CTCL. Also, this is
the first one to show expression of a HERV-W-encoded
protein, Syncytin-1, in the CTCL lymphocytes. Our
comprehensive microarray-based analysis identified a
characteristic skin-specific HERV transcription profile and, in
addition, certain degree of inter-individual variability in the
HERV transcription patterns, as shown in previous studies on
other human tissues (Table S1 and [39,60,63]). These
observations jointly emphasize the importance of including
paired samples of both malignant (lesion) and non-malignant
(intact, healthy) tissue to a study. Since MF is a malignancy of
sessile, non-recirculating skin-resident T-cells [3,64], and since
there are no reliable methods to selectively isolate the
malignant T-cells (and in sufficient numbers), relevant results
could be obtained only by studying skin samples directly. Of
note, even normal skin used in parallel, is known to contain
resident effector memory T-cells. The reason for also including
Figure 4.  Relative expression of ERVWE1 mRNA in MF skin tissue.  ERVWE1 expression was detected in 3/7 MF lesions
analysed by Taqman qPCR. Patients 3 and 7 were also analysed, but the MF lesions showed no ERVWE1 expression (Figure S1).
Patients 7 and 18 showed expression also in the clinically healthy (H), non-lesional skin samples (the data of patient 7 in Figure S1).
GAPDH served as internal standard and was expressed in every sample (see Methods for more details). MF patients 18 and 19
were collected afterwards and were therefore not included in other experiments. See detailed amplification curves in Figure S1.
doi: 10.1371/journal.pone.0076281.g004
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Figure 5.  Syncytin-1 protein expression is found in MF skin lesions but not in lichen planus.  A) Morphologically malignant
lymphocytes within Pautrier’s microabscesses (invading the epidermis) stained positive (red arrow) for Syncytin-1 in
immunohistochemistry, DAB 40x B) same sample as in a) but with NovaRED as a chromogen, 100x, C) same sample as in A)
without primary antibody, DAB 40x, D) Lichen ruber planus sample with no Syncytin-1 expression albeit abundant numbers of
inflammatory T cells, NovaRED 20x, E) in folliculotropic MF, Syncytin-1-positive lymphocytes protruding in the hair follicle, 20x and
F) human placenta as a positive control, 20x. Scale bar is 20µm.
doi: 10.1371/journal.pone.0076281.g005
HERV-W Expression in Mycosis Fungoides
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paired skin samples of psoriatic patients in our analyses was
based on the recent report on the transcription of three HERV
groups in psoriatic lesions, namely HERV-W, HERV-K and
HERV-E, and partially characterized a new endogenous
retroviral variant, related to the ERV-9⁄HERV-W group [48]. We
confirmed all these HERV groups to be part of a constitutively
transcribed, skin-specific HERV transcription profile. HERV-W
was among the most strongly transcribed HERV groups in MF
lesions (compared to the corresponding non-malignant skin
samples). Our identification of the specific transcribed HERV-W
elements yielded eight HERV-W loci on eight different
chromosomes. Transcripts that could be ascribed to the HERV-
W related, MS-associated retrovirus MSRV were not detected.
HERV-W is a multicopy human endogenous retrovirus group
[65] that consists of about 1300 loci (including solo LTR,
complete and partial loci [66]). In our study, HERV-W loci on
chromosomes 6q21 and 7q21.2 were identified as being
transcribed at higher levels in MF lesions (Table S2, Figure 3).
Both loci have also been found transcribed in relation to
neuroimmune diseases like MS in other studies [59,61,67].
Interestingly, frequent chromosomal alterations in CTCL also
include chromosomes 6, 7, and 17. Recurrent breakpoints or
deletions have been detected in e.g. 6q22-q25 and
chromosomal gains in chromosome 7 [7-10,46,68]. Importantly,
transformed MF tumor cells are characterized by gains of 7q21
and 17q12 among others [11]. Also, among patients with
chronic lymphocytic leukemia (CLL) or with CTCL, the second
most frequent chromosomal abnormalities were
rearrangements involving 6q21-23 [69].
Syncytin-1 is a retroviral protein encoded by the HERV-W
locus on chromosome 7q21.2 (official gene name: ERVWE1)
[70]. It is a key player in human placental development,
especially during fusion of cytotrophoblasts [54-56].
Cytotrophoblasts fuse to generate multinuclear
syncytiotrophoblasts that function as pregnancy hormone
factory [71,72]. Besides these beneficial physiological
functions, Syncytin-1 is also capable of inducing
neuroinflammation [44,73]. Fusogenic properties of Syncytin-1
outside the placenta are not well understood. Expression of
Syncytin-1 outside the placenta has been reported, capable of
activating a pro-inflammatory and autoimmune cascade
through receptors CD14 and TLR4 (Toll-Like Receptor 4) on
antigen-presenting cells, and also of triggering dysregulation of
T-lymphocytes in multiple sclerosis (MS) [74]. ERVWE1-
encoded Syncytin-1 protein expressed in MS is currently
considered as an important therapeutic target. HERV-W
elements appear associated with MS but it remains unclear
whether they are triggers or markers.
Interestingly, we found most prominent Syncytin-1
expression in the morphologically malignant lymphocytes within
the Pautrier´s microabscesses (Figure 5A-B) and also within
the lymphocyte infiltrate invading hair follicles in folliculotropic
MF (Figure 5E). The mechanism for the unique
epidermotropism of malignant lymphocytes in MF has not been
elucidated completely, although certain skin adressins like
integrins, CLA and CCR4 play a role in general [64,75]. Our
findings warrant further functional and prospective follow-up
studies on the role of Syncytin-1 in the process of CTCL
development.
Conclusions
We report, for the first time, the transcription of HERVs in
MF, the most common form of CTCL. However, it is still
unclear, whether the elevated expression of HERV-W
transcripts is due to malignant transformation, immune
activation, or even physiological functions. Nevertheless, we
also show the expression of a HERV-W-encoded protein,
Syncytin-1, in skin-resident (i.e. skin-homing, non-recirculating)
MF lymphocytes but not in non-malignant, skin-homing or skin-
resident lymphocytes. Our study offers a new perspective into
the pathogenesis of CTCL and it is tempting to speculate that
Syncytin-1 could act as a proinflammatory stimulus in MF
microenvironment in a similar fashion as in MS [43,44,76]. Still,
we cannot totally exclude a possibility that HERV expression
may only be a consequence of an inflammatory context
although we did not detect any Syncytin-1 protein within the
lymphocytic inflammatory infiltrates of lichen ruber planus. As a
conclusion, we suggest that HERVs up regulated in various
subsets of patients may represent promising candidates for
future prospective studies identifying potential clinical
correlates in CTCL and even novel therapeutic targets.
Methods
Ethics Statement
The study was approved by the Medical Ethical Review
Board of Helsinki University Central Hospital and all patients
provided a written informed consent. The investigation has
been conducted according to the principles expressed in the
Declaration of Helsinki.
Patient samples and sample preparations
Surgical biopsies of both lesional and clinically healthy, non-
lesional (i.e. non-malignant) skin were obtained from 12
patients with the common MF subtype of CTCL (10 with stage
IA-IVA disease and two with folliculotropic MF) and five
psoriasis patients, treated at the Skin and Allergy Hospital,
Helsinki University Central Hospital (HUCH, Finland). The
study was approved by the Medical Ethical Review Board of
Helsinki University Central Hospital and all patients provided a
written informed consent. None of the patients was infected
with HIV-1 or with HTLV-I as determined with routine serology
(www.huslab.fi). A total of 34 tissue samples were embedded
in RNA stabilization reagent (Qiagen) immediately after
surgery, immersed over night at +4°C and stored at -20°C or
-70°C. RNA was extracted using RNeasy Mini Kit (Qiagen) and
RNA was stored at -20°C or -70°C. Total RNA was incubated
with 1 µl DNaseI (10 U/µl, recombinant, RNase-free, Roche
Diagnostics, Mannheim, Germany) to remove genomic DNA.
RNA quantity was measured by NanoDrop ND1000 (PeqLab
Biotechnologie GmbH, Erlangen, Germany). About 25 ng of
each RNA preparation was tested for DNA contamination by
control PCR with mixed oligonucleotide primers (MOP) [37].
Only RNA preparations negative for PCR products in 3%
HERV-W Expression in Mycosis Fungoides
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e76281
agarose gel electrophoresis were used for subsequent reverse
transcription with RevertAid First Strand cDNA Synthesis Kit
(Fermentas, Helsinki, Finland) and for all consecutive
RetroArray and qRT-PCR experiments. In all PCR
experiments, negative controls were performed to exclude false
positive signals derived from DNA contaminations.
For the additional experiments, we were able to collect
another set of skin tissue samples (both lesion and clinically
healthy) from five of the original MF patients with persistent
disease (patients 1, 3, 5, 7, and 8) and from two recent MF
patients (18 and 19). The RNA was extracted as described
above. Additionally, RNA was also extracted from five formalin
fixed and paraffin-embedded (FFPE) samples of lichen ruber
planus using automated QIASymphony SP/AS instrument
(Qiagen) which is designed and optimized especially for the
purification of sufficient quality RNA from FFPE material. The
reverse transcription into cDNA was performed using
SuperScript®-VILO cDNA Synthesis kit (11754-050,
Invitrogen). Moreover, additional 26 randomly selected,
archival MF lesion and five lichen ruber planus FFPE samples
(the same samples were used for RNA extraction, see above)
were collected for Syncytin-1 IHC analysis.
Retrovirus-specific Microarray (RetroArray)
The RetroArray consists of 48 representative HERV RT-
derived sequences from 20 major HERV groups. For design of
these capture probes, databases were screened for RT-related
sequences, which were then classified according to the current
nomenclature and further subgrouped with respect to their
degree of nucleotide similarity. Representative members of
each subgroup were selected with special emphasis on full-
length proviral genomes and retroviral sequences that have
been associated previously in literature with any biological
activities and/or human diseases (see Table S1 in [77]). Mixed
oligonucleotide primer (MOP) sequences were derived from
two highly conserved amino acid motifs commonly found in all
retroviral reverse transcriptase genes. Discrimination between
different HERV subgroups was achieved by internal sequences
of the amplification product. The internal sequences are
specific for each HERV subgroup and bind to oligonucleotides
(capture probes) spotted on the chip [37].
RetroArray hybridization probe synthesis, labelling by MOP
PCR as well as printing, blocking, hybridization, and
postprocessing of retrovirus-specific microarrays were
performed as described previously [37,78,79]. Hybridized
microarrays representing triplicates of the same array on the
same chip were scanned using an Affymetrix GMS-418
scanner (laser power setting, 100%; gain setting, 50%), and
the resulting images (16-bit TIFF files) were subjected to
qualitative analysis using ImaGene 4.0 software (BioDiscovery,
Inc., Los Angeles, USA). Exclusively arrays showing
reproducible hybridization patterns in triplicate subarrays were
further evaluated. Densitometric data were used for
discrimination of positive signals from background.
As described in the study of [60], an arbitrary cut-off value
corresponding to twofold background intensity values of the
respective chip was used to discriminate between positive and
negative signals. This proved to be in good agreement with the
optical appearance of raw images when observed on a colour-
calibrated monitor in a darkened room. To account for the
influence of mRNA quality, HERV signals were compared to
RNA levels of the gene HPRT, a housekeeping gene showing
the most consistent transcript levels in urothelial tissues. Since
RetroArray is in principle a qualitative method due to some
design limitations (i.e. use of degenerate primers) as discussed
in extenso [77,79,80], HERV groups showing signals above the
mentioned cut-off value were evaluated as active regardless of
their signal strength. It should be noted that each positive
RetroArray signal may represent multiple HERV loci of one
subgroup of multicopy HERV elements with sufficient sequence
similarity to preclude identification of individual HERV loci. The
original array data is available upon request from the authors.
Relative quantification of HERV-W transcripts
Quantitative real-time PCR was performed with the Roche
LightCycler 1.5 System, using LightCycler® 480 DNA SYBR
Green I Master Mix according to the manufacturer’s
instructions (Roche, Mannheim, Germany). For amplification of
pol (reverse transcriptase domain) sequences, specific primers
for group HERV-W (forward primer: TGAGTCAATTCTCAT-
ACCTG, reverse primer: AGTTAAGAGTTCTTGGGTGG) were
used [37]. The primers were designed in such a way that one
primer matches the capture probe sequences used for the
microarray experiments whereas the second primer is located
70 bp downstream of the first primer. Three independent
replicates of amplifications were performed using a 10 minutes
denaturation step at 95°C, followed by 40 cycles of 10 sec at
95°C, 5 sec at 60 °C, and 10 sec at 72°C. RNA-Polymerase II
(RPII) transcripts were analyzed as internal standard, using
primers given in [81]. To confirm specific amplification PCR
products were further analyzed by melting curve analysis and
by agarose gel electrophoresis (data not shown). The relative
expression ratio was calculated as described [82] and
statistical significance was measured using Two-Way ANOVA
as implemented in the SPSS (Statistical Package for the Social
Sciences) statistics software package (Figure 2).
Identification of transcribed HERV loci
HERV-W specific RT-PCR products (HERV-W-derived
transcripts) from patients 1, 5, 6, and 12 were purified
(NucleoSpin Extract II, Macherey-Nagel, Düren, Germany) and
cloned into the pGEM T-Easy vector (Promega) and
transformed into TOP10F bacterial cells. Plasmid DNA was
isolated from insert-containing colonies according to the
manufacturer’s protocol (NucleoSpin Plasmid, Macherey-
Nagel, Düren, Germany). Sequences of cloned RT-PCR
products were determined using an Applied Biosystems 3730x
Capillary Sequencer and using vector-specific primers (SeqIt
GmbH, Kaiserlautern, Germany). The quality of sequencing
chromatograms was assessed and poor quality reads were
excluded from subsequent analysis.
We assigned sequences of cloned cDNAs to HERV-W
genomic loci by BLAT searching the hg18 human reference
genome sequence at the UCSC Genome Browser, employing
randomly distributed and therefore characteristic sequence
differences between the various HERV-W loci that allow
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discrimination between single loci [38,59,63] (Table S2, Figure
3).
We note that relative quantitation by RetroArray and qRT-
PCR and identification of transcribed HERV-W loci utilized
different primer sets. The RetroArray capture probes and qRT-
PCR primers were located within the HERV-W pol gene.
Primers for identification of transcribed HERV-W loci are
located within the HERV-W env gene [59]. Many HERV-W loci
lack 5' portions of different length because they were formed by
L1-mediated retrotransposition [83,84]. Primers for
identification of transcribed HERV-W loci can therefore identify,
in principle, more transcribed HERV-W loci than primers used
for qRT-PCR.
ERVWE1 mRNA expression
The expression of ERVWE1 was further confirmed with
Taqman qPCR. The cDNAs were amplified on Roche
LightCycler 480 1.5 System using validated Taqman Assays
(0,5x, ERVW1, Hs00205893_m1 74bp, 0,5x GAPDH
4310884E, 118pb Life Technologies) and iQ Supermix
(170-8860, Bio-Rad). The size and the purity of the amplicon
was checked with agarose gel electrophoresis (3% SeaKem®
LE agarose, Rockland, ME, USA, 1xTBE). GAPDH served as
internal standard.
Immunohistochemistry
Syncytin-1 protein was detected in formalin-fixed paraffin-
embedded (FFPE) skin tissue samples of patients 1, 5, 6, and
12, obtained during the same time period as the ones used for
the original RNA extraction and before any treatments (see
Figure 2 for MF stages and section Patient samples and
sample preparations.). Additionally, archival FFPE skin
biopsies of histologically confirmed MF (n=26) and Lichen ruber
planus (n=5) were also stained. The biopsies were obtained
from untreated MF stage I - III lesions except for two cases
under Targretin + PUVA therapy or recent chemotherapy. Two
of the samples represented folliculotropic MF. The Lichen ruber
planus samples served as non-malignant reference samples
with abundant numbers of inflammatory T cells. IHC was
performed using mouse monoclonal anti-syncytin-1 antibody
(1:30, 4.38mg/ml, 1F11B10) with VECTASTAIN Elite ABC Kit
(Mouse IgG, Vector Laboratories, Peterborough, UK) according
to the manufacturers` instructions. As an antigen retrieval
method, the slides were boiled in 10 mM sodiumcitrate
buffer-0.05% Tween20, pH 6.0 for 20 minutes. The primary
antibody was incubated over night in refrigerator. DAB or
NovaRED was used as chromogen.
Detection of auto-antibodies against recombinant
HERV-Wenv protein
ELISA (Enzyme-Linked Immunosorbent Assay) was carried
out to evaluate the presence of auto-antibodies against HERV-
Wenv proteins in MF patient sera. We were able to collect sera
from 4/12 MF patients (1, 7, 8, and 12). We used HERV Partial
Recombinant Protein as an antigen (ERVWE1 116a.a.-216a.a,
NP_055405, H00030816-Q01, Novus Biologicals, UK). Wells
were coated with antigen dilution (0.75ug/ml, 22.5ng/well),
incubated over night in refrigerator and washed three times
with PBS-Tween0.05%. Blocking was done using 2% BSA/PBS
for two hours in a shaker at RT. Each serum was diluted (1:50,
1:250, and 1:1250 in 0.5% BSA/PBS) and incubated for two
hours in a shaker at RT, whereafter the plate was washed four
times with PBS-Tween0.05%, and a secondary antibody
(1:10000, goat anti-human-IgG-HRP, 109-035-098 Jackson
ImmunoResearch laboratories Inc, West Grove, PA, U.S.A)
was added and incubated for one hour in a shaker at RT. After
washing, the bound antibody was detected with 1-Step™ Ultra
TMB-Elisa reagent (34028 Thermo scientific, Rockford, IL,
U.S.A). Absorption was measured at 450 nm. Blank control
samples lacked the antigen.
Supporting Information
Figure S1.  Amplification curves of studied MF and lichen
ruber planus samples. A) ERVWE1 amplification in patient 1
(H-, MF+), B) no ERVWE1 amplification in patient 3, C) no
ERVWE1 amplification in patient 5, D) ERVWE1 amplification
in patient 7 (H+, MF-), E) no ERVWE1 amplification in patient
8, F) ERVWE1 amplification in patient 18 (H+, MF+), G)
ERVWE1 amplification in patient 19 (H-, MF+), H) GAPDH
amplification in all studied MF samples (red), also negative
water controls are shown (green baseline), I) no ERVWE1
amplification in any of the Lichen ruber planus samples (n=5),
and J) GAPDH (red) versus ERVWE1 (green) amplification of
all studied Lichen ruber planus samples. Also negative water
controls are presented (green baseline). H= clinically healthy,
non-lesional, MF= MF lesion, + indicates amplification, - no
amplification.
(PDF)
Table S1.  Comparison of HERV core transcription pattern
in human tissues.
(PDF)
Table S2.  Summary of assignment of lesion and non-
malignant skin tissue derived cDNA sequences to specific
HERV-W loci.
(PDF)
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